| Structure | Chemical Name | CAS | MF |
|
5 -DMT-2 -OTBDMS-N2 (4-TBU-PHENOXY) ACETY G-3 -CE-
|
|
|
|
|
DMT-PROTECTED MOE-METHYL URIDINE
|
|
|
|
|
5′-DMTr-Deoxy-2′-TFA-aminouridine
|
|
|
|
5'-DMT-RIBO ADENOSINE (N-BZ)
|
81246-82-4
|
C38H35N5O7
|
|
5'-DMT-RIBO GUANOSINE (N-IBU)
|
|
C35H37N5O8
|
|
|
(-)-DOB
|
43061-15-0
|
|
|
|
5 -DMT-2 -TBDMSI-5-ME-URIDINE
|
|
|
|
|
5'-DMT-T C6 (NH-TFA) AMIDITE
|
|
|
|
|
5'-DMT-T C6 (NH-TFA)-PHOSPHATE-CPG
|
|
|
|
|
5'-DMT-T C6 (NH-TFA)-SUC-CPG
|
|
|
|
|
5'-DMT-T C6 LEV AMIDITE
|
|
|
|
|
DMT-T (5'-Dimethoxytrityl-T)
|
|
|
|
DMT-THYMIDINE H-PHOSPHONATE TRIETHYLAMMONIUM SALT
|
|
C37H48N3O9P
|
|
|
DMT-THYMIDINE 2-CLPH DIESTER BARIUM)
|
82225-23-8
|
|
|
|
DMT-2,2'-SULFONYLDIETHANOL AMIDITE
|
|
|
|
|
5'-DMT-T-Q LINKER CPG
|
|
|
|
|
DMT-1 transporter
|
|
|
|
|
Doa kinase
|
|
|
|
|
5'-DMT-T-SUC-CPG
|
|
|
|
|
3'-DMT-T-SUC-CPG
|
|
|
|
|
DOBANE102
|
96538-21-5
|
|
|
|
DOBANOL25-3S/27
|
|
|
|
|
DOBANOL91-6
|
|
|
|
|
DOBANOL45-11
|
|
|
|
|
DOBANOL
|
|
|
|
|
DOBANOL91-8
|
|
|
|
|
DOBANE102SULPHONATE
|
|
|
|
|
DOBANOL23-4.5/6
|
|
|
|
|
DOB-41 antibiotic
|
115666-98-3
|
|
|
|
Dobanol 25-3S70
|
127545-86-2
|
|
|
|
Dobanol 25-3
|
58391-12-1
|
|
|
|
DOBANOL45-7
|
|
|
|
|
DOBANOL23
|
|
|
|
|
5'-DMT-U-SUC-CPG
|
|
|
|
|
(-)-D-Nle-Gly-OH
|
|
|
|
|
4.4'-Doa,omp Diphenylamine Sulfate
|
|
|
|
D-M-TYROSINE
|
|
C9H11NO3
|
|
|
Doberol
|
5711-18-2
|
|
|
|
DOAPP protocol
|
|
|
|
|
DOA protocol
|
|
|
|
|
DOA4 protein
|
|
|
|
DO3A-T-BU-ESTER
|
|
C26H50N4O6
|
|
|
D-NMA
|
|
|
|
|
docanol
|
|
|
|
Docarpamine
|
74639-40-0
|
C21H30N2O8S
|
|
|
D.M.Water
|
|
|
|
|
DOB MEDIUM
|
|
|
|
|
DNL1L protein
|
|
|
|
|
DMWD protein
|
|
|
|
Docetaxel Metabolites M1 and M3 (Mixture of Diastereomers)
|
|
C43H51NO15
|
|
Docetaxel
|
125354-16-7
|
C45H55NO15
|
|
DOCETAXEL-[2-BENZOYL, RING-14C(U)]
|
|
C43H53NO14
|
|
DOCETAXEL SIDE CHAIN NO 1
|
152089-12-8
|
C18H25NO5
|
|
Docetaxel trihydrate
|
148408-66-6
|
C43H53NO14.3H2O
|
|
DOCETAXEL, [2-BENZOYL, RING-14C]
|
|
C43H53NO14
|
|
|
Docetaxel
|
|
|
|
Docetaxel
|
114977-28-5
|
C43H53NO14
|
|
DOCETAXEL, [2-BENZOYL 2,3,5-3H]
|
|
C43H50NO14T3
|
|
|
Docetaxel injections
|
|
|
|
|
Docetaxel trihydrouse
|
|
|
|
|
DOCETAXEL SIDE CHAIN
|
|
|
|
|
Docetaxel for Injection
|
|
|
|
Docetaxel intermediate
|
114915-14-9
|
C43H53NO14
|
|
Docetaxel-D9
|
940867-25-4
|
C43H53NO14
|
|
|
Docetaxel Impurity A
|
|
C41H55NO14
|
|
Docetaxel-d5
|
|
C43H53NO14
|
|
D-(-)-N-(1-METHOXYCARBONYL-1-PROPEN-2-YL)-ALPHA-AMINO-(4-HYDROXYPHENYL)-ACETIC ACID POTASSIUM SALT
|
|
C13H14KNO5
|
|
D-N-METHYLPHENYLALANINOL
|
|
C10H15NO
|
|
Docetaxel Metabolite M4
|
157067-34-0
|
C43H49NO15
|
|
Docetaxel Hydroxy-tert-butyl-carbamate
|
154044-57-2
|
C43H53NO15
|
|
(+/-)DOB, [PROPYL-1,2-3H]-
|
|
C11H14BrNO2T2
|
|
|
DMV protocol
|
|
|
|
|
DMV regimen
|
|
|
|
|
DOBS055
|
|
|
|
|
D(-)O-CHLORO-PHENYLGLYCINE
|
|
|
|
|
docidrazin
|
|
|
|
DOC 2 (13-37) [HOMO SAPIENS]/[RATTUS NORVEGICUS]/[MUS MUSCULUS]
|
|
C130H205N37O34S2
|
|
|
DOBSJN
|
|
|
|
|
DODA 501
|
|
|
|
5,6-Dimethylxantheonone-4-acetic acid
|
117570-53-3
|
C17H14O4
|
|
|
DOCK1(DEDICATOROFCYTO-KINESIS1),DOCK180,~150-200KD,GOATANTI-HUMAN:WB
|
|
|
|
|
DOCKERS
|
|
|
|
|
docking protein
|
|
|
|
|
DOCKPOLLEN
|
|
|
|
|
DOCK2 protein
|
|
|
|
|
DOCK180 protein
|
|
|
|
DODAP
|
127512-29-2
|
C41H77NO4
|
|
Dobupride
|
106707-51-1
|
C20H30ClN3O4
|
|
|
DobutamineHclUsp
|
|
|
|
DOBUTAMINE HYDROCHLORIDE
|
34368-04-2
|
C18H24ClNO3
|
|
1D-1-O-BUTYRYL-4 6-O-DIBENZOYL-MYO-INO-
|
153265-90-8
|
C24H26O9
|
|
|
Dobutramine HCl
|
|
|
|
DOBUTAMINE HYDROCHLORIDE
|
49745-95-1
|
C18H24ClNO3
|
|
DOBUTAMINE
|
|
C18H23NO3
|
|
|
Dobutamine Injection USP
|
|
|
|
dobutamine hydrochloride
|
51062-28-3
|
|
|
dobutamine hydrochloride
|
51062-26-1
|
|
|
(+)-Dobutamine
|
61661-05-0
|
|
|
1D-1-O-BUTYRYL-4,6-O-DIBENZOYL-MYO-INOSITOL
|
|
C24H26O9
|
|
dobutamine hydrochloride
|
52663-81-7
|
C18H24ClNO3
|